AlphaQuest LLC Buys 27,579 Shares of Dynavax Technologies Corporation $DVAX

AlphaQuest LLC increased its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 50.2% during the 2nd quarter, Holdings Channel reports. The firm owned 82,499 shares of the biopharmaceutical company’s stock after purchasing an additional 27,579 shares during the quarter. AlphaQuest LLC’s holdings in Dynavax Technologies were worth $818,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Choreo LLC increased its position in shares of Dynavax Technologies by 3.2% in the first quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 1,065 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Dynavax Technologies by 4.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 1,453 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dynavax Technologies by 1.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after buying an additional 1,625 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Dynavax Technologies in the first quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,304 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Dynavax Technologies news, Director Scott Dunseth Myers purchased 3,800 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was bought at an average price of $10.82 per share, with a total value of $41,116.00. Following the completion of the purchase, the director directly owned 35,004 shares of the company’s stock, valued at $378,743.28. The trade was a 12.18% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 2.98% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on DVAX shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research note on Friday. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $24.33.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $10.38 on Monday. The firm has a market cap of $1.22 billion, a PE ratio of -22.57 and a beta of 1.13. Dynavax Technologies Corporation has a fifty-two week low of $9.20 and a fifty-two week high of $14.63. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The business has a 50 day moving average price of $10.02 and a 200-day moving average price of $10.32.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The firm had revenue of $95.44 million during the quarter, compared to analyst estimates of $87.55 million. Equities research analysts predict that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.